Officials in Hainan, China, granted Shuangcheng Pharmaceuticals (SHE:002693) a license to produce Albuvirtide injection for HIV on behalf of Frontier Biopharmaceuticals (Nanjing), according to a Saturday filing with the Shenzhen bourse.
Shares closed 2% higher on Monday.
The permit is valid for three years.
Shuangcheng also obtained approval to produce the Bivalirudin anticoagulant injection on behalf of Suzhou Erye Pharmaceutical, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments